Journals / Turkish Journal of Gastroenterology / 2022 / Cilt: 33 - Sayı: 4

Treatment Adherence of Anti-TNF Drugs in the Patients with Inflammatory Bowel Disease: A Scale Development Stud

Pages
336–345
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result of all mea- surements, it was determined that it is a valid and reliabl

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: This work studies the validity and reliability of the Anti-TNF Alpha Treatment Adherence Scale, which has newly been developed to measure the compliance of inflammatory bowel disease patients using the anti-TNF alpha agents that are widely used in gastroenterology and rheumatology clinics.
📊
Key Findings & Data:Methods: The study group consisted of 165 irritable bowel disease patients aged 18 years and above who were using anti-TNF alpha drugs.
💡
Conclusion & Impact:As a result of all mea- surements, it was determined that it is a valid and reliabl
🔬Design:Lab & Field Experiment
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: This work studies the validity and reliability of the Anti-TNF Alpha Treatment Adherence Scale, which has newly been developed to measure the compliance of inflammatory bowel disease patients using the anti-TNF alpha agents that are widely used in gastroenterology and rheumatology clinics. Methods: The study group consisted of 165 irritable bowel disease patients aged 18 years and above who were using anti-TNF alpha drugs. After creating a question pool with 40 items, the pilot study was applied with 70 patients. SPSS 25.0 and AMOS programs were used. Item-total correlation coefficients, Cronbach’s alpha and test-retest analysis, missing data, extreme value, normality, 27% sub- upper item discrimination analysis, and exploratory and confirmatory factor analyses were used. Results: The factor structure of the scale was examined with exploratory and confirmatory factor analyses and the contribution of these components to the total variance was measured as 74.21%. The Anti-TNF Alpha Treatment Adherence Scale was found in relation to the scale structure consisting of 12 items and 4 sub-dimensions. According to the first level multifactorial analysis results, the goodness of fit identities of the scale were found at an acceptable level, with the following values: RMSEA 0.067; GFI 0.92; AGFI 0.87; CFI 0.95; and χ2 79.876 (P = .000). Conclusion: It was determined that the Anti-TNF Alpha Treatment Adherence Scale represents the area to be measured, measures the researched structure, has a high internal consistency between items, is interrelated, and is consistent over time. As a result of all mea- surements, it was determined that it is a valid and reliabl

🔖

Cite This Article

BAŞAK, N., URAN, B. N. Ö., YÜKSEL, E. S. (2022). Treatment Adherence of Anti-TNF Drugs in the Patients with Inflammatory Bowel Disease: A Scale Development Stud. Turkish Journal of Gastroenterology, Cilt: 33 - Sayı: 4, 336–345. https://ajindex.com/articles/408409

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Udalova I, Monaco C, Nanchahal J, Feldmann M. Anti-TNF therapy. Microbiol Spectr. 2016
  2. 4(4):1-11. [CrossRef] 2. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr. 2010
  3. 20(2):87-103. [CrossRef] 3. Aydın V, Akıcı A. TNF-alpha inhibitor-induced infections in rheu- matic diseases. tjtfp. 2018
  4. 9(1):13-24. [CrossRef] 4. Tezel A. İnflamatuvar barsak hastaliklarinda anti-TNF tedavilerin yeri ve Uygulamada dikkat edilecek noktalar. Güncel Gastroenter- oloji. 2010
  5. 14(4):193-197. 5. van Hoeve K, Hoffman I, Vermeire S. Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease. Expert Opin Drug Saf. 2017
  6. 17(2):185-196. [CrossRef] 6. Üzerk M, Çetinkaya H. Ülseratif kolitin klasik tedavisine genel bakış ve anti-TNF ajanlarin rolü. Güncel Gastroenteroloji. 2009
  7. 13(1):41-47. 7. TİTCK. 2016/7 Genelgesi: Anti-TNF İlaçlar. Available at: https://ww w.san liurf aeo.o rg.tr /indi r3-22 5428J G8ANT %DD%2 0TNF. pdf, Accessed July 7, 2019. 8. Sabaté E, WHO Adherence to Long Term Therapies Project, Global Adherence Interdisciplinary Network, World Health Organization. Department of Management of Non-Communicable Diseases. Adherence to Long-Term Therapies: Evidence for Action. Geneva: World Health Organization
  8. Toh CT, Jackson B, Gascard DJ, Manning AR, Tuck EJ. Barriers to medication adherence in chronic heart failure patients during home visits. J Pharm Pract Res. 2010
  9. 40(1):27-30. [CrossRef] 10. Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treat- ment of inflammatory bowel disease. World J Gastroenterol. 2016
  10. 22(3):1078-1087. [CrossRef] 11. Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013
  11. [CrossRef] 12. Vural B, Acar ÖT, Topsever P, Filiz TM. Modifiye Morisky Ölçeğinin Türkçe Geçerlilik Güvenilirlik Çalışması. Turk Fam Phys. 2012
  12. 3(4):17-20. 13. Aydın B, Gelal A, Kullanımı Aİ. Yaygınlaştırılması ve tıp Eğitiminin rolü. DEÜ Tıp Fak Derg. 2012
  13. 26(1):57-63. 14. Nordgaard-Lassen I, Dahlerup JF, Belard E, et al. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012
  14. 59(7):C4480. 15. Kelly MM, Turner BS, Kappelman MD, Lee EJ, Gulati AS. Imple- mentation and evaluation of a standard operating procedure for pediatric infliximab infusions. Pediatr Qual Saf. 2019
  15. 4(1):e137. [CrossRef] 16. Mie